# A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program

> **NCT00236600** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 561 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** topiramate

## Key facts

- **NCT ID:** NCT00236600
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** 2002-06
- **Target enrollment:** 561 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236600, "A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00236600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*